As a university professor-founded company, we are currently producing and selling an atopic dermatitis cream that has demonstrated outstanding efficacy, with extremely positive market feedback.

Globally, the number of atopic dermatitis patients is estimated to be in the hundreds of millions, and the market size is projected to exceed 10 trillion KRW (approximately USD 7 billion). Despite the large market, no existing product has truly satisfied patients’ needs—until now.

Sol-Ato24 Cream has received remarkably high satisfaction ratings from users, offering new hope for those suffering from chronic skin conditions.